Rintatolimod

A new combination therapy for triple-negative breast cancer (TNBC) showed promising results in Phase I clinical trials, with 66% of patients achieving remission. Conducted by Roswell Park Comprehensive Cancer Center, the therapy involved neoadjuvant chemotherapy and a chemokine modulatory regimen (CKM) with paclitaxel and rintatolimod, interferon alfa-2b, and celecoxib, resulting in no immune-related adverse events. The study concluded that the regimen was safe and effective, with findings published in the British Medical Journal.

New TNBC treatment at Roswell Park achieves 66% complete remission without immune-related adverse events, using a combination of chemotherapy and immunotherapy.

Preliminary DURIPANC trial data show rintatolimod + durvalumab combo maintains stable disease in 2/3 late-stage pancreatic cancer patients at 6 months, with no toxicity observed. Patients continue treatment, with ongoing assessments for disease progression.